TDCs to Treat Drug-resistant Epilepsy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2017-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epilepsy is the fourth overall neurologic disorder, regardless of age and gender. It encompass a wide spectrum of conditions, intensities and seizure types; therefor, several drugs have proven to treat different types of seizures. However, around 22.5 % of patients are unable to attain control regardless of the drug used or even a combination of several of them. TDCs offers a non-invasive approach with a focal effect for those patients. The focus of this study is to define the role for tDCS in the treatment of drug-resistant epilepsy on children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Transcranial Direct Current Stimulation to Treat Epilepsy

NCT05673915

Focal Epilepsy Generalized Onset Epilepsy Sleep-related Epileptic Encephalopathy

RECRUITING NA

Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

NCT06334952

Epilepsy Drug Resistant Epilepsy

RECRUITING NA

High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy

NCT06241963

Transcranial Direct Current Stimulation EEG Functional Magnetic Resonance Imaging +2 more

RECRUITING NA

Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy

NCT04782869

Epilepsy

COMPLETED NA

Transcranial Direct Current to Treat Epilepsy at Home

NCT04309812

Epilepsies, Partial

ENROLLING_BY_INVITATION EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epilepsy is the fourth overall neurologic disorder, regardless of age and gender. There are between 16 and 51 new cases per 100 000 people every year. A community-based study conducted in France concluded that up to 22.5 % of patients could be classified as presenting drug-resistant epilepsy. This group presents significant hazards such as an increased risk of death, injuries, psychosocial disfunction and a reduced quality of life. The International League against Epilepsy defines drug-resistant epilepsy as follows: A failure of adequate trials of two (or more) tolerated, appropriately chosen, appropriately used antiepileptic drugs (whether administered as monotherapies or in a combination) to achieve freedom from seizures. This significant amount of patients are the drive to develop different approaches in order to offer alternatives for control. In this regard, non-invasive brain stimulation protocols lead the way, since the pathophysiological substrate of epilepsy is an enhanced cortical excitability, leading to paroxysmal depolarisation shifts, an enhanced probability of high-frequent and hypersyncronous activity of small neuronal networks and the abnormal spreading of this pathological activity along cortico-cortical and cortico-subcortical neuronal conections. Transcranial direct current stimulation (tDCS) consists of short-lasting electric stimulus delivered to specific brain regions. When delivered repidetly, it generates long-lasting cortical excitability alterations and thus, has the potential to treat epilepsy targeting to the specific brain region where the cortical excitability is alterated. The aim of this study is to define the role for tDCS on the treatment of drug resistant epilepsy on children.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Other Forms of Epilepsy, Treatment Resistant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

we use in half of patient cathodal tDCS or Brain noninvasive stimulation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Refractory Epilepsy Group

50 patients with at least they have 3 crisis per week They Receive Cathodal tDCS We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31

Group Type EXPERIMENTAL

Cathodal tDCS

Intervention Type DEVICE

We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus

Placebo Patients

50 patients with at least they have 3 crisis per week that receive SHAM They Not Receive Cathodal tDCS. We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31

Group Type PLACEBO_COMPARATOR

Cathodal tDCS

Intervention Type DEVICE

We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cathodal tDCS

We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brain Noninvasive Electrical Stimulation tDCS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-90 montths
* Having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose.
* At least 2-3 seizure per month documented with EEG, not only clinically.
* In good health except epilepsy.
* Patients or his(her) familys could understand this method and sign the informed consent 7）Patients with good compliance and could complete postoperative follow-up.

Exclusion Criteria

* Results of MRI remind epilepsy caused by intracranial space-occupying lesions.
* Tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental disease，pepticulcer，diabetes Type 1，bad health etc, and other surgical contraindication
* sleep-related breathing disorders

Minimum Eligible Age

18 Months

Maximum Eligible Age

120 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes